Articles

Find an Article

Filter articles

Applied Filters

Showing 251 to 260 of 274 results

A new approach to cancer target screening

Norway31-05-2013

BerGenBio’s ‘ask the cell’ technology could potentially change cancer treatment as we know it. With an expanding patent portfolio and library of trade secrets behind it, what challenges does the startup biotech company face in bringing its first drugs to market?

Self-collision of European patent filings: an accident waiting to happen?

EU31-05-2013Jane Wainwright

The definition of what constitutes a co-pending patent filing in Europe has recently been rewritten to include patent applications from within the same patent family. Jane Wainwright of Potter Clarkson investigates the decisions leading to this change.

A global approach: Novo Nordisk's IP strategy

EU30-04-2013

While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.

Russia v Eurasia: national and regional differences in patentability

Belarus, Kazakhstan, Russia01-04-2013Maria Nilova and Elena Tsvetkova

There are important differences between the Russian and Eurasian procedures in obtaining a patent, especially for inventions in the field of life sciences, as Maria Nilova and Elena Tsvetkova explain.

Biotech threats in the SPC system

EU01-04-2013Jaap Mannaerts

In its effort to tackle the threat of ‘evergreening’, the CJEU has caused some uncertainty about supplementary protection certificates, as Jaap Mannaerts explains.

Post-grant patent challenges in Europe and the US: harmony at last?

EU, US01-04-2013Jane Wainwright and Daniel Young

Challenging the validity of a patent through the court systems of Europe and the US can be a time-consuming and expensive process. Jane Wainwright and Daniel Young look at the alternatives.

The European take on the Bolar provision: conclusions from Astellas v Polpharma

Poland01-04-2013Rafał Witek

While changes to European law seem to allow fairly broad exemptions to the patent law for companies developing generic alternatives to branded drugs, the reality is different, as Rafał Witek explains.

Twenty-one years of SPCs – a cause for celebration?

28-03-2013

Gordon Wright reviews the key SPC cases as Europe’s SPC Regulation for medicinal products approaches its 21st birthday.

The likely role of the UPC in pharma patent litigation

EU28-03-2013

The recent agreement on a Unified Patent Court in Europe raises questions for patent holders in all industries. Trevor Cook looks at the potential impact on pharmaceutical patent litigation.

Hub and spoke? Life sciences in Northern France

France01-02-2013

It seems an unlikely place for innovation, but Lille and its surroundings play host to a burgeoning life sciences industry. LSIPR visited to find out more.

Showing 251 to 260 of 274 results

LSIPR